Is NGNE or CNTB more profitable?

Neurogene's return on equity of -37.88% beat Connect Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets Neurogene N/A -37.88% -34.70% Connect Biopharma N/A -122.29% -97.07%

Does the media favor NGNE or CNTB?

In the previous week, Neurogene had 2 more articles in the media than Connect Biopharma. MarketBeat recorded 3 mentions for Neurogene and 1 mentions for Connect Biopharma. Connect Biopharma's average media sentiment score of 1.27 beat Neurogene's score of 0.89 indicating that Connect Biopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Neurogene 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Connect Biopharma 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is CNTB or FBRX more profitable?

Forte Biosciences' return on equity of -106.17% beat Connect Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets Connect Biopharma N/A -122.29% -97.07% Forte Biosciences N/A -106.17% -85.50%

Does the media prefer CNTB or FBRX?

In the previous week, Forte Biosciences had 5 more articles in the media than Connect Biopharma. MarketBeat recorded 6 mentions for Forte Biosciences and 1 mentions for Connect Biopharma. Connect Biopharma's average media sentiment score of 1.27 beat Forte Biosciences' score of 0.73 indicating that Connect Biopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Connect Biopharma 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Forte Biosciences 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend AVTE or CNTB?

Connect Biopharma has a consensus price target of $7.29, suggesting a potential upside of 206.12%. Given Connect Biopharma's stronger consensus rating and higher probable upside, analysts clearly believe Connect Biopharma is more favorable than Aerovate Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aerovate Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Connect Biopharma 1 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 2.89

Is AVTE or CNTB more profitable?

Aerovate Therapeutics' return on equity of -90.19% beat Connect Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets Aerovate Therapeutics N/A -90.19% -77.47% Connect Biopharma N/A -122.29% -97.07%

Is IMMX or CNTB more profitable?

Immix Biopharma's return on equity of -73.24% beat Connect Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets Immix Biopharma N/A -73.24% -59.20% Connect Biopharma N/A -122.29% -97.07%

Does the media favor IMMX or CNTB?

In the previous week, Immix Biopharma had 2 more articles in the media than Connect Biopharma. MarketBeat recorded 3 mentions for Immix Biopharma and 1 mentions for Connect Biopharma. Immix Biopharma's average media sentiment score of 1.68 beat Connect Biopharma's score of 1.27 indicating that Immix Biopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immix Biopharma 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Connect Biopharma 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor DNA or CNTB?

In the previous week, Ginkgo Bioworks had 2 more articles in the media than Connect Biopharma. MarketBeat recorded 3 mentions for Ginkgo Bioworks and 1 mentions for Connect Biopharma. Connect Biopharma's average media sentiment score of 1.27 beat Ginkgo Bioworks' score of 0.00 indicating that Connect Biopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ginkgo Bioworks 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Connect Biopharma 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Connect Biopharma (CNTB) Competitors

$2.38 +0.04 (+1.71%)

Closing price 07/17/2026 04:00 PM Eastern

Extended Trading

$2.38 0.00 (0.00%)

As of 07/17/2026 07:35 PM Eastern

Compare

CNTB vs. NGNE, FBRX, AVTE, IMMX, and DNA

Should you buy Connect Biopharma stock or one of its competitors? MarketBeat compares Connect Biopharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Connect Biopharma include Neurogene (NGNE), Forte Biosciences (FBRX), Aerovate Therapeutics (AVTE), Immix Biopharma (IMMX), and Ginkgo Bioworks (DNA). These companies are all part of the "pharmaceutical products" industry.

How does Connect Biopharma compare to Neurogene?

Neurogene (NASDAQ:NGNE) and Connect Biopharma (NASDAQ:CNTB) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, analyst recommendations, profitability, valuation, media sentiment, risk, institutional ownership and earnings.

In the previous week, Neurogene had 2 more articles in the media than Connect Biopharma. MarketBeat recorded 3 mentions for Neurogene and 1 mentions for Connect Biopharma. Connect Biopharma's average media sentiment score of 1.27 beat Neurogene's score of 0.89 indicating that Connect Biopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Neurogene	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Connect Biopharma	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Neurogene currently has a consensus price target of $84.83, suggesting a potential upside of 127.37%. Connect Biopharma has a consensus price target of $7.29, suggesting a potential upside of 206.12%. Given Connect Biopharma's higher possible upside, analysts plainly believe Connect Biopharma is more favorable than Neurogene.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neurogene	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	3.00
Connect Biopharma	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89

52.4% of Neurogene shares are held by institutional investors. Comparatively, 58.7% of Connect Biopharma shares are held by institutional investors. 11.7% of Neurogene shares are held by insiders. Comparatively, 22.6% of Connect Biopharma shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Neurogene has a beta of 1.68, suggesting that its stock price is 68% more volatile than the broader market. Comparatively, Connect Biopharma has a beta of -0.23, suggesting that its stock price is 123% less volatile than the broader market.

Neurogene's return on equity of -37.88% beat Connect Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neurogene	N/A	-37.88%	-34.70%
Connect Biopharma	N/A	-122.29%	-97.07%

Connect Biopharma has lower revenue, but higher earnings than Neurogene. Neurogene is trading at a lower price-to-earnings ratio than Connect Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neurogene	$930K	633.87	-$90.35M	-$4.55	N/A
Connect Biopharma	$60K	2,497.41	-$55.48M	-$1.15	N/A

Summary

Connect Biopharma beats Neurogene on 9 of the 16 factors compared between the two stocks.

How does Connect Biopharma compare to Forte Biosciences?

Connect Biopharma (NASDAQ:CNTB) and Forte Biosciences (NASDAQ:FBRX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, risk, earnings, profitability, media sentiment and institutional ownership.

Forte Biosciences' return on equity of -106.17% beat Connect Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Connect Biopharma	N/A	-122.29%	-97.07%
Forte Biosciences	N/A	-106.17%	-85.50%

Connect Biopharma has a beta of -0.23, meaning that its share price is 123% less volatile than the broader market. Comparatively, Forte Biosciences has a beta of 2.85, meaning that its share price is 185% more volatile than the broader market.

58.7% of Connect Biopharma shares are owned by institutional investors. Comparatively, 77.6% of Forte Biosciences shares are owned by institutional investors. 22.6% of Connect Biopharma shares are owned by company insiders. Comparatively, 4.4% of Forte Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Connect Biopharma has higher revenue and earnings than Forte Biosciences. Forte Biosciences is trading at a lower price-to-earnings ratio than Connect Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Connect Biopharma	$60K	2,497.41	-$55.48M	-$1.15	N/A
Forte Biosciences	N/A	N/A	-$69.38M	-$4.64	N/A

Connect Biopharma presently has a consensus target price of $7.29, suggesting a potential upside of 206.12%. Forte Biosciences has a consensus target price of $67.00, suggesting a potential upside of 37.13%. Given Connect Biopharma's stronger consensus rating and higher possible upside, equities analysts clearly believe Connect Biopharma is more favorable than Forte Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Connect Biopharma	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89
Forte Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, Forte Biosciences had 5 more articles in the media than Connect Biopharma. MarketBeat recorded 6 mentions for Forte Biosciences and 1 mentions for Connect Biopharma. Connect Biopharma's average media sentiment score of 1.27 beat Forte Biosciences' score of 0.73 indicating that Connect Biopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Connect Biopharma	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Forte Biosciences	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Connect Biopharma beats Forte Biosciences on 10 of the 15 factors compared between the two stocks.

How does Connect Biopharma compare to Aerovate Therapeutics?

Aerovate Therapeutics (NASDAQ:AVTE) and Connect Biopharma (NASDAQ:CNTB) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, risk, earnings, profitability, valuation, dividends and institutional ownership.

In the previous week, Connect Biopharma had 1 more articles in the media than Aerovate Therapeutics. MarketBeat recorded 1 mentions for Connect Biopharma and 0 mentions for Aerovate Therapeutics. Connect Biopharma's average media sentiment score of 1.27 beat Aerovate Therapeutics' score of 0.00 indicating that Connect Biopharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Aerovate Therapeutics	Neutral
Connect Biopharma	Positive

Connect Biopharma has higher revenue and earnings than Aerovate Therapeutics. Aerovate Therapeutics is trading at a lower price-to-earnings ratio than Connect Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aerovate Therapeutics	N/A	N/A	-$75.52M	-$1.70	N/A
Connect Biopharma	$60K	2,497.41	-$55.48M	-$1.15	N/A

Aerovate Therapeutics has a beta of 0.95, meaning that its stock price is 5% less volatile than the broader market. Comparatively, Connect Biopharma has a beta of -0.23, meaning that its stock price is 123% less volatile than the broader market.

Aerovate Therapeutics' return on equity of -90.19% beat Connect Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aerovate Therapeutics	N/A	-90.19%	-77.47%
Connect Biopharma	N/A	-122.29%	-97.07%

Connect Biopharma has a consensus price target of $7.29, suggesting a potential upside of 206.12%. Given Connect Biopharma's stronger consensus rating and higher probable upside, analysts clearly believe Connect Biopharma is more favorable than Aerovate Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aerovate Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Connect Biopharma	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89

58.7% of Connect Biopharma shares are owned by institutional investors. 24.9% of Aerovate Therapeutics shares are owned by insiders. Comparatively, 22.6% of Connect Biopharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Connect Biopharma beats Aerovate Therapeutics on 11 of the 15 factors compared between the two stocks.

How does Connect Biopharma compare to Immix Biopharma?

Immix Biopharma (NASDAQ:IMMX) and Connect Biopharma (NASDAQ:CNTB) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, risk, dividends, profitability, earnings, media sentiment, valuation and institutional ownership.

Immix Biopharma has higher earnings, but lower revenue than Connect Biopharma. Immix Biopharma is trading at a lower price-to-earnings ratio than Connect Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immix Biopharma	N/A	N/A	-$29.44M	-$0.92	N/A
Connect Biopharma	$60K	2,497.41	-$55.48M	-$1.15	N/A

In the previous week, Immix Biopharma had 2 more articles in the media than Connect Biopharma. MarketBeat recorded 3 mentions for Immix Biopharma and 1 mentions for Connect Biopharma. Immix Biopharma's average media sentiment score of 1.68 beat Connect Biopharma's score of 1.27 indicating that Immix Biopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immix Biopharma	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Connect Biopharma	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

11.3% of Immix Biopharma shares are owned by institutional investors. Comparatively, 58.7% of Connect Biopharma shares are owned by institutional investors. 30.3% of Immix Biopharma shares are owned by company insiders. Comparatively, 22.6% of Connect Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Immix Biopharma presently has a consensus target price of $20.67, suggesting a potential upside of 101.63%. Connect Biopharma has a consensus target price of $7.29, suggesting a potential upside of 206.12%. Given Connect Biopharma's stronger consensus rating and higher probable upside, analysts plainly believe Connect Biopharma is more favorable than Immix Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immix Biopharma	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
Connect Biopharma	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89

Immix Biopharma has a beta of 0.09, meaning that its stock price is 91% less volatile than the broader market. Comparatively, Connect Biopharma has a beta of -0.23, meaning that its stock price is 123% less volatile than the broader market.

Immix Biopharma's return on equity of -73.24% beat Connect Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immix Biopharma	N/A	-73.24%	-59.20%
Connect Biopharma	N/A	-122.29%	-97.07%

Summary

Immix Biopharma beats Connect Biopharma on 8 of the 14 factors compared between the two stocks.

How does Connect Biopharma compare to Ginkgo Bioworks?

Ginkgo Bioworks (NYSE:DNA) and Connect Biopharma (NASDAQ:CNTB) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, media sentiment, profitability, earnings, institutional ownership and dividends.

Ginkgo Bioworks currently has a consensus price target of $8.50, suggesting a potential upside of 7.81%. Connect Biopharma has a consensus price target of $7.29, suggesting a potential upside of 206.12%. Given Connect Biopharma's stronger consensus rating and higher possible upside, analysts clearly believe Connect Biopharma is more favorable than Ginkgo Bioworks.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ginkgo Bioworks	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67
Connect Biopharma	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89

In the previous week, Ginkgo Bioworks had 2 more articles in the media than Connect Biopharma. MarketBeat recorded 3 mentions for Ginkgo Bioworks and 1 mentions for Connect Biopharma. Connect Biopharma's average media sentiment score of 1.27 beat Ginkgo Bioworks' score of 0.00 indicating that Connect Biopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ginkgo Bioworks	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Connect Biopharma	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

78.6% of Ginkgo Bioworks shares are owned by institutional investors. Comparatively, 58.7% of Connect Biopharma shares are owned by institutional investors. 12.7% of Ginkgo Bioworks shares are owned by insiders. Comparatively, 22.6% of Connect Biopharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Connect Biopharma has lower revenue, but higher earnings than Ginkgo Bioworks. Connect Biopharma is trading at a lower price-to-earnings ratio than Ginkgo Bioworks, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ginkgo Bioworks	$170.15M	3.03	-$312.76M	-$5.36	N/A
Connect Biopharma	$60K	2,497.41	-$55.48M	-$1.15	N/A

Ginkgo Bioworks has a beta of 1.77, meaning that its share price is 77% more volatile than the broader market. Comparatively, Connect Biopharma has a beta of -0.23, meaning that its share price is 123% less volatile than the broader market.

Connect Biopharma has a net margin of 0.00% compared to Ginkgo Bioworks' net margin of -215.41%. Ginkgo Bioworks' return on equity of -56.08% beat Connect Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ginkgo Bioworks	-215.41%	-56.08%	-26.06%
Connect Biopharma	N/A	-122.29%	-97.07%

Summary

Connect Biopharma beats Ginkgo Bioworks on 10 of the 17 factors compared between the two stocks.

Get Connect Biopharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CNTB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CNTB vs. The Competition

Export

Metric	Connect Biopharma	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$149.85M	$3.69B	$6.87B	$12.29B
Dividend Yield	N/A	2.17%	2.67%	9.34%
P/E Ratio	-2.07	21.03	27.25	23.90
Price / Sales	2,497.41	178.80	493.84	75.80
Price / Cash	N/A	154.08	52.99	60.41
Price / Book	3.17	8.26	10.69	6.18
Net Income	-$55.48M	$23.83M	$3.59B	$332.29M
7 Day Performance	-5.18%	-3.47%	-2.20%	-2.05%
1 Month Performance	19.00%	2.69%	1.63%	-2.18%
1 Year Performance	38.37%	45.93%	25.64%	17.67%

Connect Biopharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CNTB Connect Biopharma	4.5561 of 5 stars	$2.38 +1.7%	$7.29 +206.1%	+38.4%	$149.85M	$233K	N/A	110
NGNE Neurogene	3.3408 of 5 stars	$38.32 -3.3%	$84.83 +121.4%	+67.0%	$626.23M	$930K	N/A	90	Gap Down
FBRX Forte Biosciences	2.2572 of 5 stars	$44.12 +0.5%	$67.00 +51.9%	+380.0%	$609.86M	N/A	N/A	5	Gap Down
AVTE Aerovate Therapeutics	N/A	$20.95 -6.8%	N/A	+119.3%	$607.24M	N/A	N/A	20	Gap Down High Trading Volume
IMMX Immix Biopharma	3.6406 of 5 stars	$10.52 -5.3%	$20.67 +96.5%	+245.1%	$604.51M	N/A	N/A	9	News Coverage Short Interest Increase

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CNTB) was last updated on 7/19/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Connect Biopharma (CNTB) Competitors

CNTB vs. NGNE, FBRX, AVTE, IMMX, and DNA

How does Connect Biopharma compare to Neurogene?

Summary

How does Connect Biopharma compare to Forte Biosciences?

Summary

How does Connect Biopharma compare to Aerovate Therapeutics?

Summary

How does Connect Biopharma compare to Immix Biopharma?

Summary

How does Connect Biopharma compare to Ginkgo Bioworks?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CNTB vs. The Competition

Connect Biopharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Connect Biopharma (CNTB) Competitors

CNTB vs. NGNE, FBRX, AVTE, IMMX, and DNA

How does Connect Biopharma compare to Neurogene?

Does the media favor NGNE or CNTB?

Do analysts prefer NGNE or CNTB?

Do insiders & institutionals hold more shares of NGNE or CNTB?

Which has more risk and volatility, NGNE or CNTB?

Is NGNE or CNTB more profitable?

Which has stronger earnings & valuation, NGNE or CNTB?

Summary

How does Connect Biopharma compare to Forte Biosciences?

Is CNTB or FBRX more profitable?

Which has more risk and volatility, CNTB or FBRX?

Do insiders and institutionals hold more shares of CNTB or FBRX?

Which has stronger valuation and earnings, CNTB or FBRX?

Do analysts recommend CNTB or FBRX?

Does the media prefer CNTB or FBRX?

Summary

How does Connect Biopharma compare to Aerovate Therapeutics?

Does the media prefer AVTE or CNTB?

Which has better earnings & valuation, AVTE or CNTB?

Which has more volatility and risk, AVTE or CNTB?

Is AVTE or CNTB more profitable?

Do analysts recommend AVTE or CNTB?

Do insiders & institutionals hold more shares of AVTE or CNTB?

Summary

How does Connect Biopharma compare to Immix Biopharma?

Which has higher earnings and valuation, IMMX or CNTB?

Does the media favor IMMX or CNTB?

Do institutionals and insiders hold more shares of IMMX or CNTB?

Do analysts recommend IMMX or CNTB?

Which has more risk & volatility, IMMX or CNTB?

Is IMMX or CNTB more profitable?

Summary

How does Connect Biopharma compare to Ginkgo Bioworks?

Do analysts recommend DNA or CNTB?

Does the media favor DNA or CNTB?

Do institutionals & insiders hold more shares of DNA or CNTB?

Which has preferable valuation and earnings, DNA or CNTB?

Which has more risk and volatility, DNA or CNTB?

Is DNA or CNTB more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CNTB vs. The Competition

Connect Biopharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools